Track topics on Twitter Track topics that are important to you
ZURICH, Sept 23 (Reuters) - AC Immune, the Swiss biotech company working on treating Alzheimer's disease, has boosted the size of its initial public offering (IPO) to raise nearly $58 million it needs to continue research on its products.
Original Article: UPDATE 1-Swiss biotech firm AC Immune increases IPO sizeNEXT ARTICLE
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...